Vijaya Diagnostic Centre Approves FY26 Results, Recommends ₹2 Dividend, Plans Acquisition

Vijaya Diagnostic Centre Ltd announced its audited financial results for the fiscal year ended March 31, 2026, following a board meeting. The company's board has recommended a final dividend of ₹2 per equity share, pending shareholder approval at the upcoming Annual General Meeting (AGM). The diagnostic chain also plans to acquire Medinova's MRI, EEG, and NCV services business for ₹4.20 crore to expand its service offerings.

Key Decisions: Dividend, Acquisition, and ESOPs

The board approved the audited standalone and consolidated financial results for the fiscal year ending March 31, 2026. The recommended final dividend of ₹2 per equity share will be put forth for shareholder approval at the AGM. In a move to expand its service portfolio, the company announced it would acquire the MRI, EEG, and NCV Services Business from Medinova Millennium MRI Services LLP for approximately ₹4.20 crore. Additionally, 1,79,500 Employee Stock Options (ESOPs) were granted under the VDCL Employee Stock Option Plan 2018, with an exercise price of ₹784 per option. Independent Director Dr. D. Nageshwar Reddy will conclude his term on May 25, 2026, and will not seek re-appointment.

Strategic Rationale and Impact

The acquisition of Medinova's diagnostic services is expected to strengthen Vijaya Diagnostic Centre's presence in specific imaging and neurological diagnostic segments, potentially driving revenue growth. The recommended dividend signals a commitment to returning value to shareholders, a positive sign for investors. Granting ESOPs is a common strategy to retain and incentivize key employees, aligning their interests with company performance.

Expansion History

Vijaya Diagnostic Centre, a prominent diagnostic chain in South India, has been actively expanding its geographical reach and service capabilities. In April 2022, the company acquired Niramaya Diagnostics for around ₹30 crore, a move aimed at bolstering its network in Kerala. This acquisition strategy, coupled with organic expansion, is part of VDCL's plan to deepen its market penetration and offer a wider array of diagnostic solutions.

What This Means for Stakeholders

Shareholders can anticipate a dividend payout, subject to AGM approval. The company's service basket will broaden with the addition of MRI, EEG, and NCV services. Employees may see enhanced motivation through the granted stock options. The strategic acquisition signals a continued focus on inorganic growth.

Factors to Monitor

The finalization of the acquisition is subject to customary closing conditions and requires approximately three months to complete. The approved financial results for FY26 did not contain specific profit or revenue figures in this announcement, making immediate assessment of year-end performance difficult. The departure of an Independent Director, while not indicating immediate risk, warrants observation for future board composition and governance continuity.

Competitive Landscape

Vijaya Diagnostic Centre operates in a competitive landscape alongside players like Dr. Lal PathLabs and Metropolis Healthcare. Dr. Lal PathLabs, a market leader with strong brand recall, focuses predominantly on North India. Metropolis Healthcare offers a pan-India presence, excelling in specialized testing and digital integration, particularly in Western and Southern regions. Krsnaa Diagnostics targets government contracts for accessible healthcare. VDCL's move to acquire specific imaging services aligns with peers' strategies of expanding service lines and market share through both organic and inorganic means.

Key Financial Data

• As of FY2025, Vijaya Diagnostic Centre reported consolidated revenue of ₹550.1 crore.
• For FY2025, consolidated Profit After Tax (PAT) stood at ₹80.5 crore.
• The company recommended a final dividend of ₹2 per equity share for FY26.
• The planned acquisition of Medinova's business is valued at approximately ₹4.20 crore.

Looking Ahead

Investors will track shareholder approval for the recommended final dividend at the forthcoming AGM. The successful completion of the acquisition of Medinova's MRI, EEG, and NCV services business is another key event. Details regarding the AGM date and the ex-dividend/record dates for dividend distribution are anticipated. Future announcements providing specific financial performance figures for FY26 will be important for assessing the year's results.